INNOVENT BIOLOGICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.15 HKD | +1.56% |
|
+17.92% | -8.42% |
| 04-17 | Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer | CI |
| 04-02 | Hutchmed endometrial cancer treatment application accepted for review | AN |
Chart calendar Innovent Biologics, Inc.
46a8e4.RXZTLWIbGplZHGdG0-kSOH-ulVbvd09OqIP_hiRlsIk.dztgfVtELOEte1Z_sr5CbDHa3zSKEyUU_eqF7nUOhb4oDDVrKn1LyRJ7DA~6d5bb76a60bbaf39fe0c2c5bf51afe7d
Upcoming events on Innovent Biologics, Inc.
Past events on Innovent Biologics, Inc.
| 09/04/2024 21:30 | American Association for Cancer Research Meeting - Abstract Number: 5295 |
| 08/04/2024 21:30 | American Association for Cancer Research Meeting - Abstract Number: 2718 |
| 07/04/2024 21:30 | American Association for Cancer Research Meeting - Abstract Number: LB056 |
| 07/04/2024 21:30 | American Association for Cancer Research Meeting - Abstract Number: LB055 |
| 07/04/2024 21:30 | American Association for Cancer Research Meeting - Abstract Number: LB057 |
| 19/03/2024 | Q4 2023 Earnings Release |
| 30/11/2023 | European Society for Medical Oncology Asia Congress - Abstract No #: 106P |
| 30/11/2023 | European Society for Medical Oncology Asia Congress - Abstract No #: LBA12 |
| 28/09/2023 10:30 | International Myeloma Society Meeting - Abstract No:P-290 |
| 28/09/2023 10:30 | International Myeloma Society Meeting - Abstract No:P-288 |
| 12/09/2023 | Morgan Stanley Global Healthcare Conference |
| 23/08/2023 12:14 | Q2 2023 Earnings Release |
| 11/06/2023 10:30 | European Hematology Association Hybrid Congress - Abstract Number : S216 |
| 07/06/2023 | European Hematology Association Hybrid Congress - Abstract Number : P1406 |
| 07/06/2023 | European Hematology Association Hybrid Congress - Abstract Number : P1099 |
| 05/06/2023 14:00 | American Society of Clinical Oncology Conference - Abstract Number : LBA 6002 |
| 01/06/2023 | American Society of Clinical Oncology Conference - Abstract Number : e14578 |
| 01/06/2023 | American Society of Clinical Oncology Conference - Abstract Number : 8025 |
| 01/06/2023 | American Society of Clinical Oncology Conference - Abstract Number : 11540 |
| 01/06/2023 | American Society Of Clinical Oncology Meeting - Abstract Number : 3586 |
Annual results
| Fiscal Period | December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
|
Net sales Million CNY | Released Forecast Spread | 9,48 13,7 -30.91% | 1 048 845 24.03% | 3 844 3 237 18.74% | 4 270 4 122 3.59% | 4 556 4 802 -5.12% | 6 206 5 968 3.99% |
|
EBITDA Million CNY | Released Forecast Spread | -1 431 -995 -43.87% | -1 638 -1 410 -16.21% | -242 -781 68.95% | -3 045 -1 820 -67.27% | -2 747 -2 505 -9.64% | -600 -990 39.41% |
|
EBIT Million CNY | Released Forecast Spread | -1 495 -1 023 -46.19% | -1 676 -1 474 -13.66% | -310 -820 62.13% | -3 113 -1 990 -56.43% | -3 066 -2 839 -8% | 0,00 -1 494 - |
|
Earnings before Tax (EBT) Million CNY | Released Forecast Spread | -5 873 -794 -640.14% | -1 720 -1 556 -10.51% | -859 -733 -17.19% | -3 051 -1 893 -61.17% | -2 170 -2 620 17.16% | 0,00 -1 136 - |
|
Net income Million CNY | Released Forecast Spread | -5 771 -704 -719.41% | -1 720 -1 513 -13.69% | -998 -737 -35.51% | -3 138 -1 884 -66.52% | -2 179 -2 644 17.58% | 0,00 -1 197 - |
|
EPS CNY | Released Forecast Spread | -5,00 -0,67 -641.19% | -1,46 -1,21 -20.33% | -0,74 -0,53 -39.41% | -2,16 -1,32 -63.14% | -1,46 -1,74 16.04% | 0,00 -0,75 - |
| Announcement Date | 14/03/19 | 30/03/20 | 29/03/21 | 29/03/22 | 28/03/23 | 20/03/24 |
Quarterly results
| Fiscal Period | December | 2019 S1 | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 Q4 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million CNY | Released Forecast Spread | 346 242 42.95% | 702 548 28.01% | 984 1 267 -22.35% | 2 860 2 828 1.1% | 1 942 1 992 -2.53% | 2 328 2 039 14.2% | 2 240 2 103 6.53% | 400 | 2 317 2 113 9.62% | 2 702 2 572 5.02% | 3 505 3 419 2.51% | 3 594 | 4 158 |
|
EBIT Million CNY | Released Forecast Spread | -1 148 -483 -137.93% | -1 960 -1 494 -31.19% | -1 212 -1 204 -0.69% | -1 617 -1 715 5.7% | -719 -1 124 36.03% | -897 | -741 | -960 | |||||
|
Earnings before Tax (EBT) Million CNY | Released Forecast Spread | -1 876 -969 -93.59% | -999 -1 079 7.42% | -1 172 -1 529 23.38% | -256 -955 73.18% | -736 | ||||||||
|
Net income Million CNY | Released Forecast Spread | -1 963 -969 -102.55% | -950 -1 120 15.1% | -1 229 -1 595 22.96% | -139 -887 84.3% | -885 | ||||||||
|
EPS CNY | Released Forecast Spread | -0,84 | -0,46 | -0,28 0,39 -171.79% | -0,81 -0,24 -237.5% | -1,35 -0,91 -48.35% | -0,65 -1,02 36.27% | -0,81 -1,11 26.7% | -0,09 -0,70 87.05% | -0,60 | ||||
| Announcement Date | 29/08/19 | 30/03/20 | 26/08/20 | 29/03/21 | 25/08/21 | 29/03/22 | 25/08/22 | - | 28/03/23 | 23/08/23 | 20/03/24 | - | - |
More events
Past sector events for Innovent Biologics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- 1801 Stock
- Calendar Innovent Biologics, Inc.
